Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) reported its financial results for the third quarter of 2025, revealing a net loss of $1.1 million, a significant reduction from the $6.0 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company reported a net loss of $8.4 million, down from $13.6 million in the prior year. The decrease in losses is attributed to a reduction in general and administrative expenses, which fell to $0.4 million in Q3 2025 from $5.4 million in Q3 2024, primarily due to lower stock-based compensation costs.
The company’s total assets increased dramatically to approximately $7.4 million as of September 30, 2025, compared to $1.3 million at the end of 2024. This growth was largely driven by a substantial increase in cash reserves, which rose to $7.3 million from $1.3 million. The total liabilities also decreased to $422,807 from $680,968, reflecting a reduction in trade accounts payable and accrued liabilities. The company’s stockholders’ equity surged to $6.98 million, up from $643,037 at the end of 2024, indicating a strengthened financial position.
In terms of strategic developments, Telomir Pharmaceuticals has made significant strides in its product pipeline. The company executed a binding Letter of Intent on October 17, 2025, to acquire TELI Pharmaceuticals, which would secure worldwide rights to its lead investigational therapy, Telomir-1. This acquisition aims to consolidate the company’s intellectual property portfolio across key global markets, enhancing its potential for future collaborations and licensing opportunities. Additionally, the company has been actively raising capital, securing $3 million in equity financing from The Bayshore Trust, and generating $8.6 million from financing activities in the first nine months of 2025.
Operationally, Telomir Pharmaceuticals has not yet generated any revenue, as it remains in the preclinical stage of development for its lead candidate, Telomir-1. The company has focused on advancing its research and development efforts, with total operating costs for the nine months ending September 30, 2025, amounting to $8.4 million, down from $9.3 million in the previous year. The company anticipates that its cash reserves will be sufficient to fund operations through the third quarter of 2026, although there is substantial doubt about its ability to continue as a going concern without additional funding.
Looking ahead, Telomir Pharmaceuticals expects to incur increased expenses as it advances Telomir-1 through clinical trials and seeks regulatory approvals. The company is actively exploring opportunities for additional financing to support its operations and development plans. The successful completion of the acquisition of TELI Pharmaceuticals and the ongoing development of Telomir-1 are critical to the company’s future growth and potential revenue generation.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals develops innovative small molecule therapies targeting cellular metal imbalances, oxidative stress, and telomere maintenance. Its lead candidate, Telomir-1, aims to treat age-related diseases, rare genetic disorders like Wilson’s disease and Progeria, metabolic conditions such as Type 2 diabetes, and viral infections. The company focuses on preclinical research, regulatory approval, and potential market expansion in aging, neurodegeneration, and chronic diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.